Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden.

MLA

Gong, Jun, et al. “Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden.” JCO Precision Oncology, vol. 4, May 2020. EBSCOhost, https://doi.org/10.1200/PO.18.00391.

APA

Gong, J., Patel, S., Adashek, J. J., Frishberg, D., Guan, M., Placencio-Hickok, V. R., Gangi, A., Gresham, G., Tuli, R., Chae, Y. K., Kurzrock, R., & Hendifar, A. E. (2020). Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. JCO Precision Oncology, 4. https://doi.org/10.1200/PO.18.00391

Chicago

Gong, Jun, Sandip Patel, Jacob J Adashek, David Frishberg, Michelle Guan, Veronica R Placencio-Hickok, Alexandra Gangi, et al. 2020. “Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden.” JCO Precision Oncology 4 (May). doi:10.1200/PO.18.00391.